重症监护病房脓毒症相关肝损伤风险预测模型的开发与评价
本研究为回顾性队列研究,使用MIMIC-IV v2.2数据库中8549例脓毒症患者,其中SALI组1067例、非SALI组7482例,按7:3随机分为训练集和验证集。在训练集中经LASSO回归和多因素Logistic回归筛选出8个独立危险因素:腹腔感染(OR=4.046)、使用血管加压素(OR=2.188)、CRRT(OR=1.928)、RDW(OR=1.109)、PLT(OR=0.996)、PT(OR=1.042)、乳酸(OR=1.154)和SOFA评分(OR=1.119)。基于这些因素构建列线图预测模型,训练集AUC 0.830(95%CI 0.814-0.847),验证集AUC 0.847(95%CI 0.825-0.869),校准曲线与理想曲线一致性好,DCA显示模型能有效区分疾病进展与否。结论认为该模型具有一定临床预测价值。
要点
- 在8549例脓毒症患者中,腹腔感染是SALI最强的独立危险因素(OR=4.046,95%CI 3.236-5.059,P<0.001)。
- 使用血管加压素(OR=2.188,95%CI 1.778-2.694)和CRRT(OR=1.928,95%CI 1.506-2.469)与SALI风险独立相关(均P<0.001)。
- RDW(OR=1.109)、PT(OR=1.042)、乳酸(OR=1.154)和SOFA评分(OR=1.119)升高与SALI风险增加独立相关,PLT(OR=0.996)升高与风险降低独立相关(均P<0.001)。
- 预测模型训练集AUC 0.830(95%CI 0.814-0.847),验证集AUC 0.847(95%CI 0.825-0.869),校准曲线与理想曲线一致性好。
- DCA曲线提示该模型能有效区分患者是否发生疾病进展。
适用人群与场景
- ICU中诊断为脓毒症的患者,数据来源于MIMIC-IV v2.2数据库。
- 按是否发生SALI分为SALI组(1067例)和非SALI组(7482例)。
研究设计与关键结果
- 研究类型为回顾性队列研究,最终队列8549例脓毒症患者,SALI组1067例、非SALI组7482例,按7:3随机分为训练集和验证集。
- 两组在性别、ICU入住类型、高血压、器官衰竭状态、感染部位(血流感染、肺部感染、腹腔感染)、生命体征、实验室指标(WBC、Hb、RDW、PLT、Alb、Tbil、AST、ALT、肌酐、血尿素氮、血钙、血钾、血钠、碳酸氢盐、AG、PT、APTT、INR、pH、PaCO2、乳酸)、治疗干预(白蛋白、去甲肾上腺素、血管加压素、CRRT、机械通气、中心静脉置管)、24小时尿量、疾病严重程度评分和预后指标上差异均有统计学意义(均P<0.05)。
- 训练集回归分析最终纳入8个指标构建预测模型:腹腔感染(OR=4.046,95%CI 3.236-5.059,P<0.001)、血管加压素(OR=2.188,95%CI 1.778-2.694,P<0.001)、CRRT(OR=1.928,95%CI 1.506-2.469,P<0.001)、RDW(OR=1.109,95%CI 1.069-1.151,P<0.001)、PLT(OR=0.996,95%CI 0.995-0.997,P<0.001)、PT(OR=1.042,95%CI 1.034-1.051,P<0.001)、乳酸(OR=1.154,95%CI 1.107-1.202,P<0.001)、SOFA评分(OR=1.119,95%CI 1.089-1.150,P<0.001)。
- ROC曲线显示训练集AUC为0.830(95%CI 0.814-0.847),验证集AUC为0.847(95%CI 0.825-0.869)。
- 校准曲线显示训练集和验证集预测值与理想曲线一致性好。
- DCA曲线提示模型能有效区分患者是否发生疾病进展。
证据类型、等级与局限
- 证据类型:回顾性队列研究,使用MIMIC-IV v2.2数据库。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,腹腔感染、血管加压素、CRRT、RDW、PLT、PT、乳酸和SOFA评分是脓毒症患者发生SALI的独立危险因素。
- 作者认为,基于上述因素构建的SALI预测模型具有一定的临床预测价值。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate independent risk factors for sepsis-associated liver injury (SALI) in intensive care unit (ICU) patients with sepsis, establish an effective risk prediction model, and validate it.
METHODS: A retrospective cohort study was conducted using patients diagnosed with sepsis from the Medical Information Mart for Intensive Care IV (MIMIC- IV) v2.2 database. Patients were divided into SALI and non-SALI groups based on the occurrence of SALI. Baseline characteristics, comorbidities, infection sites, vital signs upon ICU admission, initial laboratory parameters within 24 hours of ICU admission, treatment interventions, 24-hour urine output, disease severity scores, and prognostic indicators collected and compared between the two groups. The entire cohort was divided into training and validation sets using a 7 : 3 random sampling ratio. Independent risk factors for SALI occurrence were identified in the training set using least absolute shrinkage and selection operator (LASSO) regression analysis and multivariate Logistic regression analysis. Based on this, a risk prediction model was constructed and presented as a nomogram. Model performance was evaluated in both training and validation sets. Predictive capability was assessed using receiver operator characteristic curve (ROC curve), model calibration was determined via calibration curves, and net benefit was evaluated through decision curve analysis (DCA).
RESULTS: The final cohort included 8 549 sepsis patients, comprising 1 067 in the SALI group and 7 482 in the non-SALI group. Significant differences were observed between the two groups regarding gender, type of ICU admission, hypertension, organ failure status, site of infection (bloodstream infection, pulmonary infection, abdominal infection), vital signs, and laboratory tests [white blood cell count (WBC), hemoglobin (Hb), red cell distribution width (RDW), platelet count (PLT), albumin (Alb), total bilirubin (Tbil), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine, blood urea nitrogen, serum calcium, serum potassium, serum sodium, bicarbonate, anion gap (AG), prothrombin time (PT), activated partial thromboplastin time (APTT), international normalized ratio (INR), pH, arterial partial pressure of carbon dioxide (PaCO2), lactate], therapeutic interventions [use of albumin, norepinephrine, vasopressin, continuous renal replacement therapy (CRRT), mechanical ventilation, central venous catheterization], 24-hour urine output after ICU admission, disease severity scores, and prognostic indicators were statistically significant (all P < 0.05). After regression analysis screening of these factors in the training set, eight indicators were ultimately included in the predictive model: intra-abdominal infection [odds ratio (OR) = 4.046, 95% confidence interval (95%CI) was 3.236-5.059, P < 0.001], vasopressin (OR = 2.188, 95%CI was 1.778-2.694, P < 0.001), CRRT (OR = 1.928, 95%CI was 1.506-2.469, P < 0.001), RDW (OR = 1.109, 95%CI was 1.069-1.151, P < 0.001), PLT (OR = 0.996, 95%CI was 0.995-0.997, P < 0.001), PT (OR = 1.042, 95%CI was 1.034-1.051, P < 0.001), lactate (OR = 1.154, 95%CI was 1.107-1.202, P < 0.001), and sequential organ failure assessment (SOFA; OR = 1.119, 95%CI was 1.089-1.150, P < 0.001). ROC curves demonstrated an area under the curve (AUC) of 0.830 (95%CI was 0.814-0.847) for the training set and 0.847 (95%CI was 0.825-0.869) for the validation set. Calibration curves demonstrated good agreement with the ideal curve in both the training and validation sets. DCA curve indicated that the model could effectively distinguish between patients with and without disease progression.
CONCLUSIONS: Intra-abdominal infection, vasopressin, CRRT, RDW, PLT, PT, lactate, and SOFA score are independent risk factors for SALI in patients with sepsis. The SALI prediction model constructed based on these factors demonstrates certain clinical predictive value.
参考来源
- Lin H, Wang H. [Development and evaluation of a risk prediction model for sepsis-associated liver injury in the intensive care unit]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2025. PMID: 41500684. doi:10.3760/cma.j.cn121430-20250531-00529
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。